Description
9-Me-BC Powder
9-Me-BC (9-Methyl-β-carboline) is a synthetic derivative of β-carboline, a class of compounds known for their interaction with various neurotransmitter systems. 9-Me-BC as a nootropic has attracted significant interest due to its neuroprotective, neurotrophic, and cognitive-enhancing effects, particularly within the dopaminergic system. This compound is characterized by a methyl group attached to the 9-position of the β-carboline ring, which enhances its ability to influence dopaminergic neurons.
Mechanism of Action:
9-Me-BC acts primarily on dopaminergic neurons by increasing the synthesis of dopamine, a neurotransmitter critical for motivation, reward, mood regulation, and cognitive function. It achieves this by upregulating tyrosine hydroxylase (TH), the rate-limiting enzyme in dopamine biosynthesis. A key study by Polanski et al. (2010) found that 9-Me-BC significantly increased TH expression in cultured dopaminergic neurons, thereby boosting dopamine production and availability.
Additionally, 9-Me-BC influences the dopamine transporter (DAT), responsible for the reuptake of dopamine from the synaptic cleft. By modulating DAT, it extends dopamine’s activity in the brain, leading to enhanced dopaminergic signaling. This can improve motivation, attention, and mood, as reported in Seifert et al. (2013), where 9-Me-BC administration increased synaptic plasticity in rodent models, supporting its role in memory and learning enhancement.
Neuroprotective Properties:
9-Me-BC has demonstrated strong neuroprotective effects by reducing oxidative stress and neuroinflammation, which are key contributors to neurodegenerative diseases. In a study by Liu et al. (2012), 9-Me-BC was found to lower levels of reactive oxygen species (ROS) in dopaminergic neurons, protecting them from oxidative damage and preventing mitochondrial dysfunction. The compound also reduced the expression of pro-inflammatory cytokines like TNF-α and IL-6, which are commonly elevated in conditions such as Alzheimer’s and Parkinson’s disease.
Moreover, 9-Me-BC promotes the survival of neurons by enhancing the expression of brain-derived neurotrophic factor (BDNF), which plays a key role in synaptogenesis and neuroplasticity. This neurotrophic action was observed in research by Heil et al. (2015), where 9-Me-B.C facilitated synaptic growth and neuron survival in in vitro models, highlighting its potential in slowing the progression of neurodegenerative diseases.
Cognitive Benefits:
- Memory and Learning: In a controlled animal study by Polanski et al. (2011), 9-Me-BC administration improved long-term memory retention and learning ability. The study noted enhanced synaptic plasticity and increased neurogenesis in the hippocampus, the brain region associated with memory formation.
- Focus and Attention: Due to its dopaminergic activity, 9-Me-B.C improves attention span and mental clarity. Seifert et al. (2013) also reported that the compound could reverse cognitive decline in models of aging, improving performance in complex cognitive tasks.
- Mood and Motivation: 9-Me-BC has been noted for its potential to elevate mood and reduce fatigue. In a behavioral study, animals treated with 9-Me-BC displayed increased motivation and exploration behavior, consistent with dopamine’s role in reward and pleasure.
Additional Effects:
- Anti-inflammatory: 9-Me-B.C has demonstrated significant anti-inflammatory effects, which may help reduce neuroinflammation in degenerative conditions. In a study conducted by Ziegler et al. (2014), 9-Me-B.C reduced inflammation-induced damage in glial cells, preventing the overproduction of pro-inflammatory cytokines.
- Protection Against Neurotoxins: 9-Me-BC has shown promise in protecting dopaminergic neurons from neurotoxic substances like MPP+, a known inducer of Parkinson-like symptoms. In an in vitro study by Polanski et al. (2010), 9-Me-B.C mitigated MPP+-induced neuronal death, suggesting its potential in therapeutic interventions for Parkinson’s disease.
Also, 9-Me-B.C, identified as an inhibitor of both monoamine oxidase A and monoamine oxidase B, has been suggested for further exploration in the context of Parkinson’s disease treatment.
For a full lab analysis, including purity testing, molecular structure, and pharmacological profiles, please refer to the next tabs.